Axel Franz

Thomas Alderliesten2
Eugene Dempsey2
Petra Lemmers2
Cornelia Hagmann2
2Thomas Alderliesten
2Eugene Dempsey
2Petra Lemmers
2Cornelia Hagmann
Learn More
BACKGROUND The SafeBoosC phase II multicentre randomized clinical trial investigated the benefits and harms of monitoring cerebral oxygenation by near-infrared spectroscopy (NIRS) combined with an evidence-based treatment guideline vs. no NIRS data and treatment as usual in the control group during the first 72 h of life. The trial demonstrated a(More)
BACKGROUND Abnormal cerebral perfusion during the first days of life in preterm infants is associated with higher grades of intraventricular hemorrhages and lower developmental score. In SafeBoosC II, we obtained a significant reduction of cerebral hypoxia by monitoring cerebral oxygenation in combination with a treatment guideline. Here, we describe (i)(More)
  • 1